Vista.ai — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vista AI is a private, commercial-stage company addressing critical bottlenecks in MRI access through automation. Its core product is FDA-cleared software that automates cardiac MRI scanning protocols, demonstrably increasing throughput, consistency, and accessibility while reducing technologist burnout. Backed by clinical validation from leading institutions like Brigham and Women's Hospital, the company is positioned to expand its automation platform to other anatomical areas, leveraging AI to tackle staffing shortages and growing imaging demand.

Cardiology

Technology Platform

AI-powered software platform that automates MRI scan acquisition and planning in real-time, standardizing protocols to ensure consistent, high-quality imaging across technologists and sites.

Opportunities

The massive and growing MRI market is severely constrained by a global shortage of skilled technologists, creating a strong demand for automation solutions that boost productivity.

Vista AI can leverage its FDA-cleared platform to rapidly expand into other high-volume anatomical areas like neurology and orthopedics, dramatically increasing its total addressable market.

By enabling community hospitals to perform complex scans, the company taps into the trend of care decentralization and captures revenue currently lost to referral leakage.

Risk Factors

Commercial adoption in healthcare is slow, with long sales cycles and integration challenges that could hinder growth.

The company faces potential competition from large, established medical imaging OEMs (GE, Siemens, Philips) that could develop similar AI automation features.

Future regulatory clearances for new anatomical applications are not guaranteed and could delay pipeline expansion.

Competitive Landscape

Vista AI operates in the emerging niche of AI-driven MRI acquisition automation. Direct competitors are few, but it faces potential competition from large imaging OEMs integrating AI into their scanner platforms and from AI software companies focusing on post-processing image analysis. Its first-mover advantage with an FDA-cleared product for cardiac MRI is significant, but maintaining leadership will require rapid execution on platform expansion.

More companies in AI / Machine Learning →More companies in United States →